EP0975345A1 — (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
Assigned to Ligand UK Research Ltd · Expires 2000-02-02 · 26y expired
What this patent protects
Use of (-)-(11S,2'R)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors may be beneficial and the tre…
USPTO Abstract
Use of (-)-(11S,2'R)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors may be beneficial and the treatment or prevention of movement disorders such as Parkinson's disease, and a method of treating or preventing such disorders comprising administration of (-)-(11S,2'R)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethamol or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Nourianz (ISTRADEFYLLINE) · Kyowa Kirin
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.